Terminated PHASE2 INTERVENTIONAL 1-arm NCT00899353

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies

Sponsor: Edwards Foundation, Inc.

Conditions Chronic Lymphocytic Leukemia Monoclonal Gammopathy of Undetermined Significance Smoldering Multiple Myeloma

Updated 5 times since 2017 Last updated: Nov 18, 2013 Started: Aug 31, 2008 Primary completion: Dec 31, 2011 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Original Principal Investigator left the institution.

Other Chronic Lymphocytic Leukemia trials with similar outcome

NCT01625741 · Phase PHASE2 · May 2015

Browse all Chronic Lymphocytic Leukemia trials

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Monoclonal Gammopathy of Undetermined Significance, this trial is terminated or withdrawn. The trial is conducted by Edwards Foundation, Inc. and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Edwards Foundation, Inc.
Marshall University

Data source: Marshall University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Huntington, United States